- Home
- Signaling Pathways
- Microbiology & Virology
- Antibiotic
- Meropenem trihydrate
- Home
- Lab Reagents
- Antibiotics
- Meropenem trihydrate
Meropenem trihydrate
Meropenem trihydrate (SM-7338) is an active ingredient carbapenem antibiotic [1].
Meropenem trihydrate has shown the potent effect against gram-negative organisms with the MIC90 values of 0.03μM, 0.06μM, 0.06μM, 0.12μM,0.25μM, 0.12μM, 0.06μM, 0.12μM and 0.25μM for Escherichia coli (30), Klebsiella pneumonia(29), Klebsiella oxytoca (20), Enterobacter aerogenes (14), Enterobacter cloacae (29), Citrobacter freundii (20), Citrobacter diversus (12), proteus mirabilis (15) and Morganella morganii (15), respectively. In addition, Meropenem trihydrate has also been revealed to restrain gram-positive and anaerobic organisms with the MIC90 values of 0.008μM, 4μM and 0.015μM for Streptococcus pyogenes (20), Viridans group streptococci (27), Streptococcus pneumonia (15), respectively. Furthermore, Meropenem trihydrate has shown the different effect of pH on MIC, for example, the mean MIC values of 0.06μM and 0.03μM in pH5.5 and pH7.5, respectively [1].
References:
[1] Neu HC1, Novelli A, Chin NX.In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338.Antimicrob Agents Chemother. 1989 Jul; 33(7):1009-18.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 437.51 |
Cas No. | 119478-56-7 |
Formula | C17H31N3O8S |
Solubility | ≥20.7 mg/mL in H2O with gentle warming; insoluble in EtOH; ≥49.2 mg/mL in DMSO |
Chemical Name | (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;trihydrate |
SDF | Download SDF |
Canonical SMILES | CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O.O.O.O |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Animal experiment:[1] | |
Animal models |
Male Sprague-Dawley rats (250 ~ 350 g) with acute necrotizing pancreatitis |
Dosage form |
60 mg/kg Once daily by intraperitoneal injection |
Applications |
Meropenem treatment significantly reduced hemorrhage and fat necrosis scores, as well as the incidence of pancreatic infection. When meropenem was combined with deferoxamine, improvements could be observed in all parameters including edema, acinar necrosis, inflammatory infiltrate, hemorrhage, fat necrosis, and perivascular inflammation. However, the difference between combined treatment and meropenem treatment did not reach to statistical significance. |
Note |
The technical data provided above is for reference only. |
References: 1. Ateskan U, Mas MR, Yasar M, et al. Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas, 2003, 27(3): 247-252. |
Quality Control & MSDS
- View current batch: